Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development and Trials in Chronic Pancreatitis at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop

Pancreas. Nov/Dec 2018;47(10):1200-1207. doi: 10.1097/MPA.0000000000001174.


The lack of effective therapeutic agents specifically tailored for chronic pancreatitis (CP) has hampered clinical care and negatively impacted patients' lives. New mechanistic insights now point to novel therapies, which involve both recently developed and/or repurposed agents. This working group focused on 2 main outcomes for CP: pain and progression of disease. The goal is to frame the essential aspects of trial design including patient-centered outcomes, proposed methods to measure the outcomes of pain and progression, and study design considerations for future trials to facilitate rapid drug development for patients with CP.

Publication types

  • Congress
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Biomedical Research / methods
  • Clinical Trials as Topic / methods
  • Drug Development / methods*
  • Drug Development / trends
  • Humans
  • National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
  • Pancreatitis / drug therapy*
  • Pancreatitis, Chronic / drug therapy*
  • Pharmaceutical Preparations / administration & dosage*
  • United States


  • Pharmaceutical Preparations